Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 716
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT07634471 A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lym… |
MK-1045 | Cancer | Phase 2/3 | RECRUITING | En attente / non publié | Merck Sharp & Dohme LLC | United States, Argentina, Israel, Spain, Taiwan, Turk… | 2026-06-22 → 2035-07-23 | Ouvrir |
| NCT06406465 A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Tox… |
Belinostat | Cancer | Phase 2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · National Institutes of Health Clinica… | 2026-08-19 → 2028-07-30 | Ouvrir |
| NCT05904899 An Evaluation of the Implementation of the Care and Monitoring at Home … |
An Evaluation of the Implementati… | Cancer | À vérifier | SUSPENDED | En attente / non publié | M.D. Anderson Cancer Center | United States · MD Anderson Cancer Center, Houston, U… | 2023-08-01 → 2026-12-31 | Ouvrir |
| NCT07733908 Effectiveness of Posluma PET Scan for Post-Treatment Monitoring of Pros… |
Effectiveness of Posluma PET Scan… | Cancer | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | Aditya Bagrodia | Non communiqué | 2026-08 → 2030-07 | Ouvrir |
| NCT03436485 CYPIDES — Safety and Pharmacokinetics of ODM-208 in Patients With Metas… |
ODM-208 | Cancer | Phase 1/2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Orion Corporation, Orion Pharma | United States, Finland, France, United Kingdom · Cent… | 2018-03-19 → 2026-10-31 | Ouvrir |
| NCT06050252 Testing the Combination of the Anticancer Drug Durvalumab With Chemothe… |
Biopsy Procedure | Cancer | Phase 2 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · Boston Medical Center, Boston, United… | 2024-07-10 → 2027-02-12 | Ouvrir |
| NCT05904782 Development of Brief Positive Affect Treatment (PAT) for Caregivers of … |
Development of Brief Positive Aff… | Cancer | À vérifier | RECRUITING | En attente / non publié | M.D. Anderson Cancer Center | United States · The University of Texas M. D. Anderso… | 2025-08-29 → 2027-11-01 | Ouvrir |
| NCT05844865 Patient Derived Vascularized MicroTumor Model of Gastrointestinal Perit… |
Patient Derived Vascularized Micr… | Cancer | Non applicable | RECRUITING | En attente / non publié | University of California, Irvine | United States · Chao Family Comprehensive Cancer Cent… | 2023-05-04 → 2026-12 | Ouvrir |
| NCT06409065 Psycho-Spiritual Management for Patients With Advanced Cancer and Their… |
Psycho-Spiritual Management for P… | Cancer | Non applicable | RECRUITING | En attente / non publié | M.D. Anderson Cancer Center | United States · MD Anderson, Houston, United States | 2024-01-09 → 2028-08-31 | Ouvrir |
| NCT06875310 A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo P… |
Adagrasib | Cancer | Phase 3 | RECRUITING | En attente / non publié | Mirati Therapeutics Inc. | United States, Argentina, Australia, Austria, Belgium… | 2025-04-24 → 2032-04-30 | Ouvrir |
| NCT04858958 FAVOUR — Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 I… |
Furmonertinib 160mg | Cancer | Phase 1 | COMPLETED | En attente / non publié | Allist Pharmaceuticals, Inc. | China · Shanghai Chest hospital, Shanghai, China | 2020-08-10 → 2025-06-25 | Ouvrir |
| NCT07764887 Impacted Tooth Management and Osteoradionecrosis Risk in NPC |
Prophylactic Impacted Tooth Extra… | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | First Affiliated Hospital of Guan… | China · Affiliated Hospital of Youjiang Medical Unive… | 2026-08-30 → 2032-11-30 | Ouvrir |
| NCT07764744 OC-LEAD — Ovarian Cancer Liquid Biopsy for Early Assessment & Detection… |
Galleri Multi-Cancer Early Detect… | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Weill Medical College of Cornell … | United States · MD Anderson Cancer Center, Houston, U… | 2026-08 → 2039-07 | Ouvrir |
| NCT05864534 Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblas… |
Balstilimab | Cancer | Phase 2 | RECRUITING | En attente / non publié | Agenus Inc. | United States · Northwestern University, Chicago, Uni… | 2024-01-19 → 2031-08-31 | Ouvrir |
| NCT06890338 A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Car… |
carboplatin | Cancer | Phase 2 | RECRUITING | En attente / non publié | Bristol-Myers Squibb | United States · Atrium Health Levine Cancer Institute… | 2025-11-21 → 2030-02 | Ouvrir |
| NCT04305041 Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With … |
Pembrolizumab | Parkinson | Phase 1/2 | COMPLETED | En attente / non publié | Bristol-Myers Squibb | United States, Australia, France, Israel, Italy, Sout… | 2020-06-26 → 2025-08-25 | Ouvrir |
| NCT03076554 A Pilot Study to Investigate the Safety and Clinical Activity of Avelum… |
Avelumab | Parkinson | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · National Institutes of Health Clinica… | 2017-04-19 → 2028-03-30 | Ouvrir |
| NCT06312176 A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in C… |
Sacituzumab Tirumotecan | Parkinson | Phase 3 | RECRUITING | En attente / non publié | Merck Sharp & Dohme LLC | United States, Argentina, Australia, Belgium, Brazil,… | 2024-04-14 → 2031-04-12 | Ouvrir |
| NCT07762508 A Prospective Single-Arm Study of VABu Conditioning Regimen in Allo-HSC… |
Venetoclax | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | National Cancer Institute (NCI) | China · First Affiliated Hospital of Soochow Universi… | 2026-08 → 2029-07 | Ouvrir |
| NCT07763756 Single vs Multiple Injection Intertransverse Process Block in Breast Ca… |
Multiple Level Intertransverse Pr… | Cancer | Non applicable | NOT_YET_RECRUITING | En attente / non publié | Antalya City Hospital | Non communiqué | 2026-11-01 → 2027-09-01 | Ouvrir |
| NCT07008027 Real World Asparaginase Therapy Toxicity |
Real World Asparaginase Therapy T… | Cancer | À vérifier | NOT_YET_RECRUITING | En attente / non publié | St. Jude Children's Research Hosp… | United States · St. Jude Children's Research Hospital… | 2026-09 → 2031-07 | Ouvrir |
| NCT04431024 Prospective Evaluation of High Resolution Dual Energy Computed Tomograp… |
Prospective Evaluation of High Re… | Cancer | À vérifier | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | United States · National Institutes of Health Clinica… | 2021-03-30 → 2038-06-30 | Ouvrir |
| NCT00068003 Harvesting Cells for Experimental Cancer Treatments |
Anti-CD19 CAR PBL | Cancer | À vérifier | ENROLLING_BY_INVITATION | En attente / non publié | National Cancer Institute (NCI) | United States · National Institutes of Health Clinica… | 2003-09-08 | Ouvrir |
| NCT05534386 A Self-management Based Survivorship Intervention for Chinese Cancer Su… |
A Self-management Based Survivors… | Cancer | Non applicable | RECRUITING | En attente / non publié | The University of Hong Kong | Hong Kong · Kwong Wah Hospital-Breast Center, Hong Ko… | 2023-04-12 → 2027-12-31 | Ouvrir |
| NCT05562518 GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRo… |
Estrogen | Cancer | Phase 4 | COMPLETED | En attente / non publié | University Hospital, Ghent | Belgium · University Hospital Ghent, Ghent, Belgium | 2022-03-21 → 2026-03-02 | Ouvrir |